Review
The authors review the current treatment landscape for patients with advanced non-small-cell lung cancers harbouring a KRAS G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options.
Review
This article provides a review of the current treatment approaches to advanced non-small-cell lung cancer in patients without molecular driver alterations, with an additional focus on special populations, concomitant medications, and other considerations that might be useful for daily clinical practice.
Review
This article is a narrative review of the most current data on bispecific antibodies in B cell non-Hodgkin’s lymphoma and multiple myeloma.
Review
This article reviews the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.
Review
This article discusses the current management of this rare entity and provide an overview of the most relevant molecular findings, whilst illustrating the potential value that prescreening panels can offer, searching for actionable targets (MSI/dMMR, PD-L1, BRAFv600E) to guide therapy with promising agents that could fill a void in this disease.